A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 9, 2021

Primary Completion Date

January 18, 2022

Study Completion Date

January 18, 2022

Conditions

Atopic Asthma

Interventions

DRUG

ADX-629

ADX-629, 600 mg administered orally twice daily (PO bid) for a minimum of 1 week

DRUG

Placebo

Placebo, 600 mg administered orally twice daily (PO bid) for minimum 1 week

Trial Locations (1)

Cliantha Research, Mississauga